Brief: EMA Says CHMP Recommends Refusal Of Marketing Authorisation For Lagevrio For COVID-19 In Adults

Camurus AB

24/02/2023 11:42

Feb 24 (Reuters) - European Medicines Agency (EMA):
    * EMA- CHMP RECOMMENDED GRANTING MARKETING AUTHORISATION FOR
AKEEGA FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH
BRCA1/ BRCA 2 MUTATIONS
    * EMA: CHMP COMMITTEE ADOPTED POSITIVE OPINION FOR ELFABRIO
FOR
TREATMENT OF FABRY DISEASE
    * EMA: CHMP RECOMMENDED REFUSAL OF MARKETING AUTHORISATION
FOR
LAGEVRIO FOR TREATMENT OF COVID-19 IN ADULTS 
    * EMA- CHMP SAYS APPLICATION TO EXTEND THERAPEUTIC
INDICATION OF
BUVIDAL TO TREAT CHRONIC PAIN IN PEOPLE WITH DEPENDENCE ON
OPIOIDS WAS WITHDRAWN

 ((Reuters.Briefs@thomsonreuters.com;))